









Markets
/
Stocks
/
nasdaq-ardx
/

Ardelyx Inc

ARDX

View Detailed Chart

4.330USD

+0.090+2.12%

Close 08/01, 16:00（ET）Quotes delayed by 15 min

1.04BMarket Cap

LossP/E TTM



Ardelyx Inc

4.330

+0.090+2.12%

Overview Company Financials

Financials

Intraday

30m

Today

+2.12%

5 Days

+0.93%

1 Month

+1.41%

6 Months

-18.15%

Year to Date

-14.60%

1 Year

-28.43%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 12 analysts

BUY

Current Rating

10.818

Target Price

149.84%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

552

Total

Median

Average

Company name

Ratings

Analysts

Ardelyx Inc

ARDX

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

Ionis Pharmaceuticals Inc

IONS

IQVIA Holdings Inc

IQV

...

111

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Neutral

Sell(5)

Neutral(3)

Buy(5)

Indicators

Sell(2)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.078

Neutral

RSI(14)

52.981

Neutral

STOCH(KDJ)(9,3,3)

39.219

Buy

ATR(14)

0.182

High Vlolatility

CCI(14)

-81.387

Neutral

Williams %R

58.537

Sell

TRIX(12,20)

0.315

Sell

StochRSI(14)

87.148

Buy

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

4.282

Buy

MA10

4.329

Buy

MA20

4.428

Sell

MA50

4.047

Buy

MA100

4.358

Sell

MA200

4.876

Sell

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Ardelyx, Inc. is a biopharmaceutical company. The Company focuses on discovery, development, and commercialization of advanced medicines that meet significant unmet medical needs. It has two commercial products IBSRELA (tenapanor) and XPHOZAH. Its product pipeline includes RDX013 Program and RDX020 Program. Tenapanor is a small molecule therapy in development for the treatment of or the control of hyperphosphatemia or serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis. Tenapanor has a mechanism of action and acts locally in the gut to inhibit the sodium hydrogen exchanger 3 (NHE3). IBSRELA is developed for the treatment of patients with irritable bowel syndrome with constipation (IBS-C). XPHOZAH is a medicine for the control of serum phosphorus in adult patients with CKD on dialysis. RDX013 Program is a small molecule potassium secretagogue program for the treatment of hyperkalemia. RDX020 Program is a small molecule for treating metabolic acidosis.

Ticker SymbolARDX

CompanyArdelyx Inc

CEOMr. Michael G. (Mike) Raab

Websitehttps://www.ardelyx.com/